Spironolactone is Highly Appropriate for Hyperaldosteronism
Yes, spironolactone is the recommended first-line medical therapy for primary aldosteronism (PA), particularly for bilateral disease or when surgery is not suitable for unilateral disease. 1, 2, 3
Treatment Framework
When Spironolactone is Indicated
Medical therapy with spironolactone is the definitive treatment for:
- Bilateral adrenal hyperplasia (idiopathic hyperaldosteronism) - the most common scenario requiring lifelong medical management 2
- Unilateral PA when surgery is declined or contraindicated 3
- Preoperative preparation for patients awaiting adrenalectomy (100-400 mg daily) 3
The 2025 Endocrine Society guidelines specifically recommend spironolactone over other mineralocorticoid receptor antagonists (MRAs) due to its low cost and widespread availability 1. This is echoed by the 2024 multidisciplinary consensus identifying spironolactone as "usually the mineralocorticoid receptor antagonist of choice" 2.
Dosing Strategy
Initial dosing should be risk-stratified:
- Standard cases: Start 25 mg daily 1, 3
- Severe PA with profound hypokalemia: Consider 50 mg daily initially 1
- Medically complex/frail patients or those on ACE inhibitors/ARBs: Start 12.5-25 mg daily with careful monitoring 1
- Reduced kidney function (eGFR 30-50 mL/min/1.73m²): Consider 25 mg every other day due to hyperkalemia risk 3
Titration: Increase to 50 mg daily after tolerating 25 mg, with doses up to 100-400 mg daily for PA treatment 3. The FDA label specifies that for primary hyperaldosteronism, doses of 100-400 mg daily are appropriate 3.
Monitoring Protocol
Within 2-3 months of initiation or dose adjustment, measure:
- Serum potassium and renal function (critical for hyperkalemia detection)
- Blood pressure response
- Renin levels (as marker of adequate MR blockade) 1
The primary goal is blood pressure control; the secondary goal is achieving normokalemia 2. The 2025 guidelines suggest titrating MRA therapy to raise renin from baseline when hypertension remains uncontrolled despite treatment 1.
Clinical Effectiveness
Recent 2026 data demonstrates that low-dose spironolactone (≤50 mg) achieves equivalent blood pressure control compared to higher doses when combined with other antihypertensives, while significantly reducing adverse effects, particularly in men (29.3% vs 39.1% adverse effects) 4. This challenges the traditional approach of aggressive dose escalation.
Important Caveats
Contraindications
Do not use spironolactone in:
- Hyperkalemia (serum K+ >5.0 mEq/L at baseline)
- Advanced renal impairment
- Pregnancy 1
Common Pitfall: Adverse Effects
The most significant limitation is anti-androgenic side effects, particularly gynecomastia and sexual dysfunction in men (44.7% of men experience adverse effects vs 15.7% of women) 4. When these occur, switch to eplerenone, which requires 2-3 times higher doses (50-300 mg daily in divided doses) but has greater MR selectivity and fewer hormonal side effects 2.
Drug Interactions
Critical interactions requiring dose adjustment or avoidance:
- Potassium supplements, salt substitutes, or potassium-rich diets
- ACE inhibitors and ARBs (increased hyperkalemia risk)
- NSAIDs (reduced efficacy and hyperkalemia risk)
- Lithium (reduced clearance causing toxicity) 3
Why This Matters for Outcomes
PA patients have dramatically elevated cardiovascular risk compared to essential hypertension: 2.58-fold increased stroke risk, 3.52-fold increased atrial fibrillation, and 2.05-fold increased heart failure 2. Targeted aldosterone blockade with spironolactone reduces this excess cardiovascular morbidity and mortality, making it essential rather than optional therapy 2, 5.
The mechanism is direct MR antagonism at the aldosterone-dependent sodium-potassium exchange site in the distal renal tubule, promoting sodium and water excretion while retaining potassium 3. This addresses the pathophysiology at its source.
Food increases spironolactone bioavailability by 95.4%, so establish a consistent pattern of taking it with or without food 3.